Oral Presentation Of CytRx Corporation (CYTR)’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
8/7/2014 10:06:35 AM
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its oral presentation given by Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center, titled “Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas,” was featured in The Lancet Oncology in its July 2014 issue (Volume 15, Issue 8) in a review of the major presentations from the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.
Help employers find you! Check out all the jobs and post your resume.
comments powered by